Long-term efficacy of adalimumab in generalized pustular psoriasis

Journal of Dermatological Treatment

Volumn 19, Issue 3, 2008, Pages 185-187

  Zangrilli, Arianna ^a   Papoutsaki, Marina ^a   Talamonti, Marina ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adalimumab; Biologics; Generalized pustular psoriasis; Tumor necrosis factor alpha (TNF )

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LONG TERM CARE; MONOTHERAPY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45849112919     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701759587     Document Type: Article

References (17)

1. Griffith CEM, Christopher E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156:258-62.
2. Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: A report of 28 cases. Int J Dermatol. 1997;36:266-71.
3. Umezawa Y, Ozawa A, Kawasima T. Therapeutic guideline for the treatment of generalized pustular psoriasis (GPP) based on proposed classification of disease severity. Arch Dermatol Res. 2003;295:43-54.
4. Salfeld J, Kaymakcalan Z, Traccy D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. 1998;41(suppl):S57 (abstr).
5. Langley R, Leonardi C, Toth D, Chen DM. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2005;52(Suppl):P8.
6. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI D). J Investig Dermatol Symp Proc. 2004;9:169-80.
7. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol. 1987;12:8-11.
8. Chren MM, Lasek RJ, Plocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of skindex, a quality of life instrument for patients with skin disorders. Arch Dermatol. 1997;133:1433-40.
9. Trent TJ, Kerdel AF. Successful treatment of Von Zumbush pustular psoriasis with infliximab. J Cutan Med Surg. 2004;8:224-8.
10. Weishaupt C, Metze D, Luger TA, Stander S. Treatment of pustular psoriasis with infliximab. J Dtsch Dermatol Ges. 2007;5:397-9.
11. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155:156-9.
12. Leonardi CL, Powers JL, Matheson RT. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
13. Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis. 2006;78:197-9.
14. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269-75.
15. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open label extension study. J Am Acad Dermatol. 2006;55:598-606.
16. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat. 2005;16:350-2.
17. Tobin AM, Kirby B. Successful treatment of recalcitant acrodermatitis continua of Hallopeau with adalimumab and acitretin. Br J Dermatol. 2005;153:445-6.